BackgroundFrailty is characterized by declining homeostatic reserves and increased vulnerability to stressors, and has been associated with cognitive decline and dementia.ObjectiveTo examine the relationship between frailty, Alzheimer's disease (AD) biomarkers, and cognitive performance in individuals with mild cogniti...
Manuela Pintus, M. Valletta, L. Sacchi et al.· Journal of Alzheimer's Disea...· 0 citations
Overall, current evidence on p-tau217 is derived mainly from selected populations and may not fully reflect real-world clinical diversity, so future studies should prioritize more representative cohorts and standardized reporting of key variables will be essential to strengthen its adoption in clinical practice.
M. T. Blasi, Simona Buscarnera, M. Salzillo et al.· Ageing Research Reviews· 0 citations
Higher blood biomarker levels of AD are associated with accelerated trajectories of GS decline and earlier onset of mobility limitations, suggesting a faster decline in GS may reflect underlying neurodegeneration and indicate changes in brain health.
Javier Leal-Martín, G. Grande, Caterina Gregorio et al.· Journal of Cachexia, Sarcope...· 0 citations
Easily accessible blood-based biomarkers of AD may be linked to subsequent faster cognitive decline in the general older population, with patterns suggesting some heterogeneity across biomarkers and that individual characteristics may influence clinical interpretation.
E. J. Laukka, I. Ekström, Martina Valletta et al.· JAMA Network Open· 0 citations
In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation.
Martina Valletta, D. L. Vetrano, E. J. Laukka et al.· Annals of Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
